Ginkgo Bioworks secured a BARDA BioMaP contract worth up to $22.2 million to develop cost‑reducing, rapid domestic manufacturing for monoclonal antibodies against filoviruses, including Ebola and Sudan virus. Ginkgo will integrate process innovations across discovery, expression, and downstream production with partners such as Advanced BioScience Laboratories and ProteoNic. The award targets national biosecurity by aiming to accelerate and de‑risk mAb manufacturing for medical countermeasures. The contract underscores sustained government investment to bolster U.S. biomanufacturing capacity for high‑consequence pathogens.